The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.
本公开提供了具有MASP-2抑制活性的化合物,这些化合物的组合物,以及制造和使用这些化合物的方法。
QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
申请人:Cook, II James H.
公开号:US20090270405A1
公开(公告)日:2009-10-29
The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.
UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS
申请人:Chao Hannguang J.
公开号:US20080280905A1
公开(公告)日:2008-11-13
The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Y
1
receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y
1
receptor activity.
Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands
申请人:Cook, II James H.
公开号:US20100099684A1
公开(公告)日:2010-04-22
The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.
ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS
申请人:Achillion Pharmaceuticals, Inc.
公开号:US20160362433A1
公开(公告)日:2016-12-15
Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R
12
or R
13
on the A group is an ether (R
32
) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement.